查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1630991

溶小體酸性脂肪酶缺乏症治療市場規模、佔有率、趨勢分析報告：按適應症、按治療方法、按地區、細分市場預測，2025-2030 年

Lysosomal Acid Lipase Deficiency Treatment Market Size, Share & Trends Analysis Report By Indication (Wolman Disease, Cholesteryl Ester Storage Disease), By Treatment, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

溶小體酸性脂肪酶缺乏症治療市場的成長與趨勢：

根據Grand View Research最新報告，到2030年，全球溶小體酸性脂肪酶缺乏症治療市場規模預計將達到4.332億美元，2025年至2030年複合年成長率為7.2%。大量未滿足的需求、不斷上升的盛行率以及酵素替代療法的廣泛採用是推動市場發展的一些關鍵因素。

LAL 缺乏症 (LAL-D) 是一種罕見的溶小體貯積症，患者由於 LAL 基因突變而無法分解膽固醇酯和三酸甘油酯。結果，脂質在肝臟、脾臟和血管壁中積聚。 LAL 缺乏症是一種進行性疾病，具有多系統臨床表現、嚴重的醫療併發症以及因肝功能衰竭而過早死亡，尤其是嬰兒。

直到2015年，由於缺乏核准的治療方法，全球LAL缺乏症治療市場成長緩慢。藥物治療僅限於支持性護理，手術和他汀類藥物等調脂藥物仍是主要治療。 2015 年，酵素替代療法 (ERT) 經 Alexion Pharma 的 Kanuma（severipase alfa）核准進入 LAL-D 領域。 Kanuma 是一種特異性水解溶小體膽固醇酯和三酸甘油酯的酶，可靜脈注射給 LAL 缺乏症患者。目前，Kanuma 是主要市場上唯一核准用於沃爾曼病（WD）和膽固醇酯貯積症（CESD）的藥物。

根據治療情況，支持性護理是 2017 年市場的主要收益來源。然而，在鹿沼的持續採用的支持下，ERT 產業預計將在預測期內實現最快的成長。由於大多數患者未被診斷或誤診，該疾病的預後仍然很差。因此，仍然強烈需要進行廣泛的研究來了解疾病的生物學並開發旨在克服抗藥性和最大限度地減少毒性的有效治療方法。

溶小體酸性脂肪酶缺乏症治療市場報告要點

  • CESD 發生在晚年，在白人和西班牙裔中更為常見，影響約三十萬分之一的人。
  • 由於 ERT 類藥物的高普及率和可用性，德國處於歐洲市場的前沿。
  • Kanuma 在 ERT 類別中的核准凸顯了 LAL-D 缺乏症治療方法的根本轉變。
  • 由於 Kanuma 作為尚未開發的 LAL-D 患者群體中唯一的長期治療藥物的領先優勢，預計 ERT 領域在預測期內將成長最快。
  • 由於同類別學名藥的競爭加劇以及 Alexion 的 Kanuma 的採用增加，他汀類藥物的市場佔有率預計將下降。
  • 受 LAL 缺乏症影響的患者數量不斷增加，且治療性介入有限，這為投資該市場新治療方法開發的公司提供了重大機會。
  • 由於預後不良和藥物供應延遲而缺乏對疾病診斷的認知可能會抑制市場成長。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章溶小體酸性脂肪酶缺乏症治療市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 營商環境分析
    • 產業分析-波特五力分析
    • PESTLE分析

第4章溶小體酸性脂肪酶缺乏症治療市場：適應症業務分析

  • 指示市場佔有率，2024/2030
  • 指示細分儀表板
  • 2018-2030 年市場規模/預測與趨勢分析（依指標）
  • 沃爾曼病 (WD)
  • 膽固醇酯貯積症（CESD）

第5章溶小體酸性脂肪酶缺乏症治療市場：治療業務分析

  • 2024年及2030年治療市場佔有率
  • 治療細分儀表板
  • 2018-2030 年市場規模/預測與趨勢分析（按處理方式）
  • 酵素替代療法（ERT）
  • 支持性護理
  • 脂質改質劑
  • 其他

第6章溶小體酸性脂肪酶缺乏症治療市場：區域估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 按國家/地區分類，2018-2030
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 按國家/地區分類，2018-2030
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 按國家/地區分類，2018-2030
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 按國家/地區分類，2018-2030
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 按國家/地區分類，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 參會企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/名單
    • Alexion Pharmaceuticals, Inc.（AstraZeneca）
    • Amgen Inc.
    • BioCrick BioTech
    • Lupin
    • Merck KGaA
    • Pfizer Inc.
    • Regeneron Pharmaceuticals Inc.
    • Teva Pharmaceutical Industries Ltd
Product Code: GVR-2-68038-610-3

Lysosomal Acid Lipase Deficiency Treatment Market Growth & Trends:

The global lysosomal acid lipase deficiency treatment market size is expected to reach USD 433.2 million by 2030, registering a CAGR of 7.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. High unmet needs, rising prevalence, and increasing uptake of enzyme replacement therapy are some of the primary factors driving the market.

LAL deficiency (LAL-D) is a rare type of lysosomal storage disorder in which patients are unable to breakdown cholesteryl esters and triglycerides due to a mutation in the LAL gene. As a result, there is an accumulation of lipids in the liver, spleen, and walls of blood vessels. LAL deficiency is a progressive disease with multi-systemic clinical manifestations, significant medical complications, and early mortality due to liver failure, especially among infants.

Until 2015, the global LAL deficiency treatment market witnessed modest growth due to a lack of approved treatments for the disease. Medical care was limited to supportive care, with surgery and lipid-modifying drugs such as statins remained the mainstay for treatment. In 2015, approval of Alexion Pharma's Kanuma (sebelipase alfa) marked the entry of enzyme replacement therapy (ERT) in the LAL-D space. Kanuma is a hydrolytic lysosomal cholesterol ester and triacylglycerol specific enzyme, administered intravenously in patients with LAL deficiency. Currently, Kanuma is the only drug approved for both Wolman disease (WD) and Cholesteryl Ester Storage Disease (CESD) in the key markets.

Based on treatment, supportive care was the leading revenue contributor in the market in 2017. However, the ERT segment is expected to register the fastest growth during the forecast period, supported by continued uptake of Kanuma. Disease prognosis remains poor, as a majority of patients are either undiagnosed or misdiagnosed. Thus, there remains a strong need for extensive research to understand disease biology and develop effective therapeutic options with the goal to overcome resistance and minimize toxicity.

Lysosomal Acid Lipase Deficiency Treatment Market Report Highlights:

  • CESD manifests later in life and is more prevalent among Caucasians and Hispanic populations, affecting approximately 1 in 300,000 individuals.
  • Germany is at the forefront of the Europe market and is driven by high disease prevalence and availability of drugs in the ERT class.
  • Approval of Kanuma in ERT class highlight a fundamental shift in treatment approach to LAL-D deficiency.
  • The ERT segment is estimated to be the fastest-growing during the forecast period, owing to Kanuma's first-mover advantage as the only long-term treatment in untapped LAL-D patient population pool.
  • Statins are anticipated to lose market share due to rising competition from generics within the class and increasing uptake of Alexion's Kanuma.
  • Rising eligible patient population and limited therapeutic intervention for LAL deficiency offer a strong commercial opportunity for players to invest in developing novel treatments in this market.
  • Lack of awareness in disease diagnosis and delayed access to medications due to poor prognosis may restrain the growth of the market.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Treatment
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Lysosomal Acid Lipase Deficiency Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Lysosomal Acid Lipase Deficiency Treatment Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2030
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 4.4. Wolman Disease (WD)
    • 4.4.1. Wolman Disease (WD) Market, 2018 - 2030 (USD Million)
  • 4.5. Cholesteryl Ester Storage Disease (CESD)
    • 4.5.1. Cholesteryl Ester Storage Disease (CESD) Market, 2018 - 2030 (USD Million)

Chapter 5. Lysosomal Acid Lipase Deficiency Treatment Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2024 & 2030
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 5.4. Enzyme Replacement Therapy (ERT)
    • 5.4.1. Enzyme Replacement Therapy (ERT) Market, 2018 - 2030 (USD Million)
  • 5.5. Supportive Care
    • 5.5.1. Supportive Care Market, 2018 - 2030 (USD Million)
  • 5.6. Lipid Modifying Agents
    • 5.6.1. Lipid Modifying Agents Market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Lysosomal Acid Lipase Deficiency Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Norway
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Norway Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Denmark Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Alexion Pharmaceuticals, Inc. (AstraZeneca)
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Amgen Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. BioCrick BioTech
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Lupin
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Merck KGaA
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Pfizer Inc.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Regeneron Pharmaceuticals Inc.
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Teva Pharmaceutical Industries Ltd
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global lysosomal acid lipase deficiency treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 5 Global lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 6 North America lysosomal acid lipase deficiency treatment market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 8 North America lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 9 U.S lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 10 U.S Lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 11 Canada lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 12 Canada lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 13 Mexico lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 14 Mexico lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 15 Europe lysosomal acid lipase deficiency treatment market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 17 Europe lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 18 UK lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 19 UK Lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 20 Germany lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 21 Germany lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 22 France lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 23 France Lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 24 Italy lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 25 Italy lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 26 Spain lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 27 Spain lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 28 Norway lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 29 Norway Lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 30 Denmark lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 31 Denmark lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 32 Sweden lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 33 Sweden lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific lysosomal acid lipase deficiency treatment market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 37 Japan lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 38 Japan lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 39 China lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 40 China lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 41 India lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 42 India lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 43 Australia lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 44 Australia lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 45 South Korea lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 46 South Korea lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 47 Thailand lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 48 Thailand lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 49 Latin America lysosomal acid lipase deficiency treatment market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 51 Latin America lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 52 Brazil lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 53 Brazil lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 54 Argentina lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 55 Argentina lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Lysosomal acid lipase deficiency treatment market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 59 South Africa lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 60 South Africa lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 63 UAE lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 64 UAE lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 65 Kuwait lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 66 Kuwait lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Lysosomal acid lipase deficiency treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Indication and treatment outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Lysosomal acid lipase deficiency treatment market dynamics
  • Fig. 12 Lysosomal acid lipase deficiency treatment market: Porter's five forces analysis
  • Fig. 13 Lysosomal acid lipase deficiency treatment market: PESTLE analysis
  • Fig. 14 Lysosomal acid lipase deficiency treatment market: Indication segment dashboard
  • Fig. 15 Lysosomal acid lipase deficiency treatment market: Indication market share analysis, 2024 & 2030
  • Fig. 16 Wolman disease (WD) market, 2018 - 2030 (USD Million)
  • Fig. 17 Cholesteryl ester storage disease (CESD) market, 2018 - 2030 (USD Million)
  • Fig. 18 Lysosomal acid lipase deficiency treatment market: Treatment segment dashboard
  • Fig. 19 Lysosomal acid lipase deficiency treatment market: Treatment market share analysis, 2024 & 2030
  • Fig. 20 Enzyme replacement therapy (ERT) market, 2018 - 2030 (USD Million)
  • Fig. 21 Supportive care market, 2018 - 2030 (USD Million)
  • Fig. 22 Lipid modifying agents market, 2018 - 2030 (USD Million)
  • Fig. 23 Others market, 2018 - 2030 (USD Million)
  • Fig. 24 Lysosomal acid lipase deficiency treatment market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 North America lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. country dynamics
  • Fig. 29 U.S. lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada country dynamics
  • Fig. 31 Canada lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico country dynamics
  • Fig. 33 Mexico lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 34 Europe lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 UK country dynamics
  • Fig. 36 UK lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany country dynamics
  • Fig. 38 Germany lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 France country dynamics
  • Fig. 40 France lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Italy country dynamics
  • Fig. 42 Italy lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain country dynamics
  • Fig. 44 Spain lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 45 Norway country dynamics
  • Fig. 46 Norway lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 47 Sweden country dynamics
  • Fig. 48 Sweden lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 49 Denmark country dynamics
  • Fig. 50 Denmark lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Japan country dynamics
  • Fig. 53 Japan lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 China country dynamics
  • Fig. 55 China lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 India country dynamics
  • Fig. 57 India lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 Australia country dynamics
  • Fig. 59 Australia lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea country dynamics
  • Fig. 61 South Korea lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 62 Thailand country dynamics
  • Fig. 63 Thailand lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 65 Brazil country dynamics
  • Fig. 66 Brazil lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 67 Argentina country dynamics
  • Fig. 68 Argentina lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 69 MEA lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 70 South Africa country dynamics
  • Fig. 71 South Africa lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 72 Saudi Arabia country dynamics
  • Fig. 73 Saudi Arabia lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 74 UAE country dynamics
  • Fig. 75 UAE lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 76 Kuwait country dynamics
  • Fig. 77 Kuwait lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 78 Company categorization
  • Fig. 79 Company market position analysis
  • Fig. 80 Strategic framework